Which company develops and produces Ensidipine?

Enasidenib, also known as AG-221, is an oral, small molecule inhibitor used to treat certain types of leukemia. It is an enzyme inhibitor that mainly targets acute myeloid leukemia (AML) caused by mutations in the isomeric cysteine u200bu200bsynthase 2 (IDH2) gene.

The development and production of ensidipine is completed by the American biotechnology company Agios Pharmaceuticals (Agios Pharmaceuticals Company). Agios PharmaceuticalsFounded in 2007 and headquartered in Cambridge, Massachusetts, it is a biopharmaceutical company focused on the research and development of cancer and rare inherited metabolic diseases. The company focuses on leveraging new discoveries in cellular metabolism to discover and develop innovative treatments for cancer and other diseases.

During the development of ensidipine, Agios Pharmaceuticals was committed to a deep understanding of the molecular mechanism of leukemia and discovered the association between IDH2 gene mutations and the onset of AML. By targeting this specific biological pathway, the company successfully developed ensidipine, a new drug for the treatment of AML.

The development process of ensidipine has undergone rigorous clinical trials to verify its safety and effectiveness. After multiple clinical trials, the drug was finally approved by the U.S. Food and Drug Administration (FDA) and became an innovative drug for the treatment of specific AML patients.

The successful development and launch of ensidipine marks Agios Pharmaceuticals's important progress in the field of tumor treatment, and provides patients with AML caused by IDH2 gene mutations.patients with a new treatment option. At the same time, this also reflects the continuous innovative achievements of biotechnology companies in cancer treatment, bringing new hopes and opportunities to the medical community and patients.